Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

WHO Revises Catalog of Drug-Resistant Bacteria Posing Greatest Human Health Risks

NextEdge Admin

18 May 2024

2 min 51 sec

The World Health Organization (WHO) has unveiled its updated Bacterial Priority Pathogens List (BPPL) for 2024, spotlighting 15 families of antibiotic-resistant bacteria classified into critical, high, and medium priority categories. This initiative aims to steer research and development efforts towards combating antimicrobial resistance (AMR), a global health crisis exacerbated by the misuse of antibiotics.

Critical priority pathogens, like gram-negative bacteria resistant to last-resort antibiotics and drug-resistant Mycobacterium tuberculosis, pose severe threats due to their resistance to treatment and capacity to spread resistance genes. Gram-negative bacteria, in particular, possess innate mechanisms for evolving resistance, contributing to the proliferation of drug-resistant strains.

High priority pathogens include Salmonella, Shigella, Pseudomonas aeruginosa, and Staphylococcus aureus, which are prevalent in low- and middle-income countries and present significant challenges in healthcare settings. Additionally, antibiotic-resistant Neisseria gonorrhoeae and Enterococcus faecium demand focused research and interventions due to persistent infections and resistance to multiple antibiotics.

Medium priority pathogens, such as Streptococcus pneumoniae and Haemophilus influenzae, also require attention, especially in vulnerable populations and resource-limited settings. The BPPL underscores the urgent need for a comprehensive public health approach to address AMR, encompassing prevention, diagnosis, and appropriate treatment measures.

Changes from the 2017 list reflect the evolving landscape of AMR. Notably, the removal and addition of pathogen-antibiotic combinations highlight emerging concerns and shifts in resistance patterns. Despite certain pathogens transitioning between priority levels, investment in R&D and prevention strategies remains crucial to mitigate their impact. The WHO’s BPPL 2024 serves as a global roadmap for combating AMR, emphasizing tailored interventions to address regional variations in pathogen distribution and resistance burdens. As AMR continues to evolve, collaborative efforts guided by the BPPL are essential to safeguard public health and preserve the efficacy of antimicrobial treatments.